Home | Publications | Diseases | Asthma place holder
place holder place holder

Asthma

Global Pipeline Review & Analysis of Hematological Malignancies


Publication Date   March 2007
Publisher   Bioseeker
Product Type  
Pages   195
ISBN Number   not applicable
Product Code   BSK144
Ask a question about this product?

Price £1,665.00

approximately: $3,111 | €2,112

Summary


Introduction

The markets segments for therapeutics for hematological malignancies are numerous and complicated. The historical general conception that relatively low prevalence diseases, has been insufficient in size to allow companies to quickly regain their investment is clearly out of date. In this perspective enhanced development is expected. Among the emerging therapeutic strategies, passive and active immunotherapies have clearly continued to be leading strategies. Small molecule apoptotic inducers and kinase inhibitors are as well in the forefront

About this report

In this unique report, Global Pipeline Review & Analysis of Hematological Malignancies, BioSeeker reports on the hematological cancer pipeline by:

  • Investigator - Includes 212 investigators and partners
  • Drug - Includes 237 ""active"" drugs
  • Sub-indication - Includes 11 sub-indications
  • Developmental stage - Includes 8 developmental stages
  • Compound type - Includes 21 different compounds types
  • Targeted therapy strategy - Includes 5 different targeted therapy strategies
  • Target - Includes 97 different protein targets
  • Signaling pathway - Includes 18 different signaling pathways

All of above ""factors"" are cross referenced against each other, generating highly valuable insights in 40 figures and 53 tables. Read more below about each ""factor"" included in this cutting edge analysis

Investigator

This report includes 212 investigators and partners from all over the world

Drug

There are today more than 237 therapeutics for the treatment of hematological cancers, from early preclinical to marketed drugs. Each drug is annotated with a brief drug description

Sub-indication

  • The hematological cancer drug pipeline is broken down into 11 sub-indications:
  • Cancer, leukemia, acute lymphocytic
  • Cancer, leukemia, acute myelogenous
  • Cancer, leukemia, chronic lymphocytic
  • Cancer, leukemia, chronic myelogenous
  • Cancer, leukemia, general
  • Cancer, leukemia, hairy cell
  • Cancer, lymphoma, B-cell
  • Cancer, lymphoma, general
  • Cancer, lymphoma, Hodgkin`s
  • Cancer, lymphoma, non-Hodgkin`s
  • Cancer, lymphoma, T-cell

Only the highest developmental stage per drug and indication is accounted for

Developmental Stage

Each sub-indication of a drug is described with its developmental stage:

Preclinical

  • Clinical Trial
  • Phase I Clinical Trial
  • Phase II Clinical Trial
  • Phase III Clinical Trial
  • Pre-registration
  • Registered
  • Marketed
  • Compound Type

BioSeeker has described all 237 drugs in the hematological malignancies pipeline with its corresponding compound type:

  • Biological
  • Biological, bacterial cells
  • Biological, cellular, autologous
  • Biological, cellular, heterologous
  • Biological, nucleic acid
  • Biological, nucleic acid, non-viral vector
  • Biological, nucleic acid, viral vector
  • Biological, peptide
  • Biological, peptide, recombinant
  • Biological, protein
  • Biological, protein, antibody
  • Biological, protein, recombinant
  • Chemical, semisynthetic
  • Chemical, synthetic
  • Chemical, synthetic, isomeric
  • Chemical, synthetic, nucleic acid
  • Chemical, synthetic, peptide
  • Natural product
  • Natural product, animal
  • Natural product, bacterial
  • Natural product, plant

When available, drug compounds are further described with chemical name, CAS number, chemical formula and molecular weight

Targeted Therapy Strategy

This report categorizes available drugs into 5 major targeted therapy strategies:

  • 1.Angiogenesis
  • 2. Antibody
  • 3. Apoptosis
  • 4. Protein Kinase Inhibitors
  • 5. Vaccines

Target

This analysis includes 97 protein targets, linked to 165 drugs for the treatment of hematological cancers. All protein targets are described by its primary localization, molecular class, molecular function, and biological process:
Primary Localization of Target:

  • Cell surface
  • Centrosome
  • Cytoplasm
  • Cytosol
  • Endoplasmic reticulum
  • Extracellular
  • Integral to membrane
  • Lysosome
  • Mitochondrial membrane
  • Mitochondrion
  • Nucleus
  • Plasma membrane
  • Secretory granule

Molecular Class of Target:

  • Adapter molecule
  • Adhesion molecule
  • Cell cycle control protein
  • Cell surface receptor
  • Chaperone
  • Cysteine protease
  • Cytokine
  • Cytokine receptor
  • Cytoskeletal protein
  • DNA methyltransferase
  • DNA polymerase
  • DNA repair protein
  • Enzyme: Deaminase
  • Enzyme: Decarboxylase
  • Enzyme: Hydrolase
  • Enzyme: Ligase
  • Enzyme: Oxidoreductase
  • Enzyme: Phosphorylase
  • Enzyme: Topoisomerase
  • Enzyme: Transferase
  • G protein coupled receptor
  • Growth factor
  • Integral membrane protein
  • Ligand
  • Lipid phosphatase
  • Membrane bound ligand
  • MHC complex protein
  • Nuclear receptor
  • Receptor tyrosine kinase
  • Serine protease
  • Serine/threonine kinase
  • T cell antigen receptor
  • Transcription factor
  • Transcription regulatory protein
  • Translation regulatory protein
  • Transport/cargo protein
  • Tyrosine kinase
  • Unclassified

Molecular Function of Target:

  • Carboxy-lyase activity
  • Cell adhesion molecule activity
  • Chaperone activity
  • Cysteine-type peptidase activity
  • Cytokine activity
  • Deaminase activity
  • DNA repair protein
  • DNA topoisomerase activity
  • DNA-directed DNA polymerase activity
  • DNA-methyltransferase activity
  • G-protein coupled receptor activity
  • Growth factor activity
  • Hydrolase activity
  • Kinase activity
  • Ligand-dependent nuclear receptor activity
  • Ligase activity
  • Lipid phosphatase activity
  • MHC class I receptor activity
  • Molecular function unknown
  • Oxidoreductase activity
  • Phosphorylase activity
  • Protein binding
  • Protein serine/threonine kinase activity
  • Protein-tyrosine kinase activity
  • Receptor activity
  • Receptor binding
  • Receptor signaling complex scaffold activity
  • Serine-type peptidase activity
  • Structural constituent of cytoskeleton
  • T cell receptor activity
  • Transcription factor activity
  • Transcription regulator activity
  • Transferase activity
  • Translation regulator activity
  • Transmembrane receptor activity
  • Transmembrane receptor protein tyrosine kinase activity
  • Transporter activity
  • Unclassified

Biological Process of Target:

  • Anti-apoptosis
  • Apoptosis
  • Cell communication
  • Cell communication ; Cell surface receptor linked signal transduction
  • Cell communication ; Signal transduction
  • Cell communication ; Signal transduction ; Transport
  • Cell growth and/or maintenance
  • Enzyme linked receptor protein signaling pathway ; Cellular morphogenesis during differentiation
  • Immune response
  • Metabolism
  • Metabolism ; Energy pathways
  • Protein metabolism
  • Protein modification
  • Regulation of cell cycle
  • Regulation of nucleobase, nucleoside, nucleotide and nucleic acid metabolism
  • Signal transduction
  • Transport

Signaling Pathway

The 97 available protein targets have been compared with molecular entities in known signaling pathways. This analysis showed the involvement of hematological drugs in at least 18 different signaling pathways:

  • Alpha6 Beta4 Integrin Signaling Pathway
  • Androgen Receptor Signaling Pathway
  • B Cell Receptor Signaling Pathway
  • EGFR1 Signaling Pathway
  • ID Signaling Pathway
  • IL-1 Singaling Pathway
  • IL-2 Signaling Pathway
  • IL-3 Signaling Pathway
  • IL-4 Signaling Pathway
  • IL-5 Signaling Pathway
  • IL-6 Signaling Pathway
  • IL-7 Signaling Pathway
  • Kit Receptor Signaling Pathway
  • Notch Signaling Pathway
  • T Cell Receptor Signaling Pathway
  • TGF-beta Receptor Signaling Pathway
  • TNF-alpha Signaling Pathway
  • Wnt Signaling Pathway

Content


  • 1 Executive Summary
  • 2 Cancer Highlights
    • 2.1 List Of Figures
    • 2.2 List Of Tables
  • 3 Players In The Field Of Hematological Malignancies
  • 4 The Hematological Cancer Drug Pipeline
    • 4.1 Drug Pipeline By Leukemia
    • 4.2 Drug Pipeline By Lymphoma
  • 5 Protein Targets In Hematological Cancers
    • 5.1 Pursued Targets In Leukemia
    • 5.2 Pursued Targets In Lymphoma
  • 6 Compounds
    • 6.1 Overview Of Compounds
    • 6.2 Presentation Of Biological Compounds Used In Hematological Cancers
    • 6.3 Presentation Of Chemical Compounds Used In Hematological Cancers
    • 6.4 Presentation Of Natural Compounds Used In Hematological Cancers
    • 6.5 Leukemia By Compound Types
    • 6.6 Lymphoma By Compound Type
  • 7 Targeted Therapies In Hematological Cancers
    • 7.1 Targeted Therapies In Leukemia
    • 7.2 Targeted Therpies In Lymphoma
  • 8 Targeted Therapy Strategies Versus Compound Types In
    • 8.1 Targeted Therapy Strategies Versus Compound Types In Leukemia
    • 8.2 Targeted Therapy Strategies Versus Compound Types In Lymphoma
  • 9 Pursued Signaling Pathways In Hematological Cancers
    • 9.1 Alpha6 Beta4 Integrin Signaling Pathway
      • 9.1.1 Description Of Pathway
      • 9.1.2 Hematological Cancer Drug Candidates
    • 9.2 Androgen Receptor Signaling Pathway
      • 9.2.1 Description Of Pathway
      • 9.2.2 Hematological Cancer Drug Candidates
    • 9.3 B Cell Receptor Signaling Pathway
      • 9.3.1 Description Of Pathway
      • 9.3.2 Hematological Cancer Drug Candidates
    • 9.4 Egfr1 Signaling Pathway
      • 9.4.1 Description Of Pathway
      • 9.4.2 Hematological Cancer Drug Candidates
    • 9.5 Id Signaling Pathway
      • 9.5.1 Description Of Pathway
      • 9.5.2 Hematological Cancer Drug Candidates
    • 9.6 Il-1 Signaling Pathway
      • 9.6.1 Description Of Pathway
      • 9.6.2 Hematological Cancer Drug Candidates
    • 9.7 Il-2 Signaling Pathway
      • 9.7.1 Description Of Pathway
      • 9.7.2 Hematological Cancer Drug Candidates
    • 9.8 Il-3 Signaling Pathway
      • 9.8.1 Description Of Pathway
      • 9.8.2 Hematological Cancer Drug Candidates
    • 9.9 Il-4 Signaling Pathway
      • 9.9.1 Description Of Pathway
      • 9.9.2 Hematological Cancer Drug Candidates
    • 9.10 Il-5 Signaling Pathway
      • 9.10.1 Description Of Pathway
      • 9.10.2 Hematological Cancer Drug Candidates
    • 9.11 Il-6 Signaling Pathway
      • 9.11.1 Description Of Pathway
      • 9.11.2 Hematological Cancer Drug Candidates
    • 9.12 Il-7 Signaling Pathway
      • 9.12.1 Description Of Pathway
      • 9.12.2 Hematological Cancer Drug Candidates
    • 9.13 Kit Receptor Signaling Pathway
      • 9.13.1 Description Of Pathway
      • 9.13.2 Hematological Cancer Drug Candidates
    • 9.14 Notch Signaling Pathway
      • 9.14.1 Description Of Pathway
      • 9.14.2 Hematological Cancer Drug Candidates
    • 9.15 T Cell Receptor Signaling Pathway
      • 9.15.1 Description Of Pathway
      • 9.15.2 Hematological Cancer Drug Candidates
    • 9.16 Tgf-Beta Receptor Signaling Pathway
      • 9.16.1 Description Of Pathway
      • 9.16.2 Hematological Cancer Drug Candidates
    • 9.17tnf-Alpha Signaling Pathway
      • 9.17.1 Description Of Pathway
      • 9.17.2 Hematological Cancer Drug Candidates
    • 9.18 Wnt Signaling Pathway
      • 9.18.1 Description Of Pathway
      • 9.18.2 Hematological Cancer Drug Candidates
  • 10 Brief Drug Description
  • 11 Disclaimer
    • 11.1 Liability
    • 11.2 Completeness
  • List Of Figures
    • Figure 1: The Hematological Cancer Developmental Pipeline
    • Figure 2: The Leukemia Developmental Pipeline
    • Figure 3: The Lymphoma Developmental Pipeline
    • Figure 4: Leukemia Drug Candidates By Developmental Stage, Sub-Indication Vrs Primary Target Localization
    • Figure 5: Leukemia Drug Candidates By Developmental Stage, Sub-Indication Vrs Biological Process Of Target
    • Figure 6: Leukemia Drug Candidates By Developmental Stage And Sub-Indication Vrs Molecular Class Of Target
    • Figure 7: Lymphoma Drug Candidates By Developmental Stage, Sub-Indication Vrs Primary Target Localization
    • Figure 8: Lymphoma Drug Candidates By Developmental Stage, Sub-Indication Vrs Biological Process Of Target
    • Figure 9: Lymphoma Drug Candidates By Developmental Stage, Sub-Indication Vrs Molecular Class Of Target
    • Figure 10: Distribution Of Compound Types In The Hematological Malignancies Pipeline
    • Figure 11: Leukemia Drug Candidates Presented By Developmental Stage And Sub-Indication Vrs Compound Type
    • Figure 12: Lymphoma Drug Candidates Presented By Developmental Stage And Sub-Indication Vrs Compound Type
    • Figure 13: Leukemia Drug Candidates By Developmental Stage And Sub-Indication Vrs Targeted Therapy Type
    • Figure 14: Lymphoma Drug Candidates By Developmental Stage And Sub-Indication Vrs Targeted Therapy Type
    • Figure 15: Angiogenesis - Developmental Stages Of Sub Indications Of Leukemia Versus Compound Type
    • Figure 16: Apoptosis - Developmental Stages Of Sub Indications Of Leukemia Versus Compound Type
    • Figure 17: Protein Kinase Inhibitors - Developmental Stages Of Sub Indications Of Leukemia Versus Compound Type
    • Figure 18: Vaccines - Developmental Stages Of Sub Indications Of Leukemia Versus Compound Type
    • Figure 19: Angiogenesis - Developmental Stages Of Sub Indications Of Lymphoma Versus Compound Type
    • Figure 20: Apoptosis - Developmental Stages Of Sub Indications Of Lymphoma Versus Compound Type
    • Figure 21: Protein Kinase Inhibitor - Developmental Stages Of Sub Indications Of Lymphoma Versus Compound Type
    • Figure 22: Vaccines - Developmental Stages Of Sub Indications Of Lymphoma Versus Compound Type
    • Figure 23: Drug Candidates Involving The Alpha6 Beta4 Integrin Signaling Pathway For The Treatment Of Hematological Cancers
    • Figure 24: Drug Candidates Involving The Androgen Receptor Signaling Pathway For The Treatment Of Hematological Cancers
    • Figure 25: Drug Candidates Involving The B Cell Receptor Signaling Pathway For The Treatment Of Hematological Cancers
    • Figure 26: Drug Candidates Involving The Egfr1 Signaling Pathway For The Treatment Of Hematological Cancers
    • Figure 27: Drug Candidates Involving The Id Signaling Pathway For The Treatment Of Hematological Cancers
    • Figure 28: Drug Candidates Involving The Il-1 Signaling Pathway For The Treatment Of Hematological Cancers
    • Figure 29: Drug Candidates Involving The Il-2 Signaling Pathway For The Treatment Of Hematological Cancers
    • Figure 30: Drug Candidates Involving The Il-3 Signaling Pathway For The Treatment Of Hematologicalcancers
    • Figure 31: Drug Candidates Involving The Il-4 Signaling Pathway For The Treatment Of Hematologicalcancers
    • Figure 32: Drug Candidates Involving The Il-5 Signaling Pathway For The Treatment Of Hematological Cancers
    • Figure 33: Drug Candidates Involving The Il-6 Signaling Pathway For The Treatment Of Hematological Cancers
    • Figure 34 Drug Candidates Involving The Il-7 Signaling Pathway For The Treatment Of Hematological Cancers
    • Figure 35: Drug Candidates Involving The Kit Receptor Signaling Pathway For The Treatment Of Hematological Cancers
    • Figure 36: Drug Candidates Involving The Notch Signaling Pathway For The Treatment Of Hematological Cancers
    • Figure 37: Drug Candidates Involving The T Cell Receptor Signaling Pathway For The Treatment Ofhematological Cancers
    • Figure 38: Drug Candidates Involving The Tgf-Beta Receptor Signaling Pathway For The Treatment Ofhematological Cancers
    • Figure 39: Drug Candidates Involving The Tnf-Alpha Signaling Pathway For The Treatment Ofhematological Cancers
    • Figure 40: Drug Candidates Involving The Wnt Signaling Pathway For The Treatment Of Hematologicalcancers
  • List Of Tables
    • Table 1: List Of Active Players In The Field Of Hematological Malignancies
    • Table 2: The Leukemia Developmental Pipeline
    • Table 3: The Lymphoma Developmental Pipeline
    • Table 4: List Of Pursued Protein Targets In Hematological Cancers
    • Table 5: Hematological Cancer Targets By Investigator And Drug
    • Table 6: Pursued Targets By Sub-Indications Of Leukemia
    • Table 7: Pursued Targets By Sub-Indications Of Lymphoma
    • Table 8: Drug Candidates With Its Corresponding Compound Types Listed By Investigator
    • Table 9: List Of Biological Compounds
    • Table 10: List Of Chemical Compounds
    • Table 11: List Of Natural Compounds
    • Table 12: Developmental Stage And Sub Indication By Compounds Type In Leukemia
    • Table 13: Developmental Stage And Sub Indication Bt Compound Types In Lymphoma
    • Table 14: List Of Targeted Therapies In Leukemia
    • Table 15: List Of Targeted Therapies In Lymphoma
    • Table 16: Targeted Therapy Strategies Versus Compound Type In Leukemia
    • Table 17: Targeted Therapy Strategies Versus Compound Types In Lymphoma
    • Table 18: Targets Linking Drugs To The Alpha6 Beta4 Integrin Signaling Pathway
    • Table 19: Drugs, Listed By Sub Indication And Developmental Stage, Targeting The Alpha6 Beta Integrin Signaling Pathway
    • Table 20: Targets Linking Drugs To The Androgen Receptor Signaling Pathway
    • Table 21: Drugs, Listed By Sub Indication And Developmental Stage, Targeting The Androgen Receptor Signaling Pathway
    • Table 22: Targets Linking Drugs To The B Cell Receptor Signaling Pathway
    • Table 23: Drugs, Listed By Sub Indication And Developmental Stage, Targeting The B Cell Receptor Signaling Pathway
    • Table 24: Targets Linking Drugs To The Egfr1 Signaling Pathway
    • Table 25: Drugs, Listed By Sub Indication And Developmental Stage, Targeting The Egfr1 Signaling Pathway
    • Table 26: Targets Linking Drugs To The Id Signaling Pathway
    • Table 27: Drugs, Listed By Sub Indication And Developmental Stage, Targeting The Id Signaling Pathway
    • Table 28: Targets Linking Drugs To The Il-1 Signaling Pathway
    • Table 29: Drugs, Listed By Sub Indication And Developmental Stage, Targeting The Il-1 Signaling Pathway
    • Table 30: Targets Linking Drugs To The Il-2 Signaling Pathway
    • Table 31: Drugs, Listed By Sub Indication And Developmental Stage, Targeting The Il-2 Signaling Pathway
    • Table 32: Targets Linking Drugs To The Il-3 Signaling Pathway
    • Table 33: Drugs, Listed By Sub Indication And Developmental Stage, Targeting The Il-3 Signaling Pathway
    • Table 34: Targets Linking Drugs To The Il-4 Signaling Pathway
    • Table 35: Drugs, Listed By Sub Indication And Developmental Stage, Targeting The Il-4 Signalingpathway
    • Table 36: Targets Linking Drugs To The Il-5 Signaling Pathway
    • Table 37: Drugs, Listed By Sub Indication And Developmental Stage, Targeting The Il-5 Signaling Pathway
    • Table 38: Targets Linking Drugs To The Il-6 Signaling Pathway
    • Table 39: Drugs, Listed By Sub Indication And Developmental Stage, Targeting The Il-6 Signaling Pathway
    • Table 40: Targets Linking Drugs To The Il-7 Signaling Pathway
    • Table 41: Drugs, Listed By Sub Indication And Developmental Stage, Targeting The Il-7 Signaling Pathway
    • Table 42: Targets Linking Drugs To The Kit Receptor Signaling Pathway
    • Table 43: Drugs, Listed By Sub Indication And Developmental Stage, Targeting The Kit Receptor Signaling Pathway
    • Table 44: Targets Linking Drugs To Thenotch Signaling Pathway
    • Table 45: Drugs, Listed By Sub Indication And Developmental Stage, Targeting The Notch Signaling Pathway
    • Table 46: Targets Linking Drugs To The T Cell Receptor Signaling Pathway
    • Table 47: Drugs, Listed By Sub Indication And Developmental Stage, Targeting The T Cell Receptor Signaling Pathway
    • Table 48: Targets Linking Drugs To The Tgf-Beta Signaling Pathway
    • Table 49: Drugs, Listed By Sub Indication And Developmental Stage, Targeting The Tgf-Beta Receptor Signaling Pathway
    • Table 50: Targets Linking Drugs To The Tnf-Alpha Signaling Pathway
    • Table 51: Drugs, Listed By Sub Indication And Developmental Stage, Targeting The Tnf-Alpha Signaling Pathway
    • Table 52: Targets Linking Drugs To The Wnt Signaling Pathway
    • Table 53: Drugs, Listed By Sub Indication And Developmental Stage, Targeting The Wnt Signaling Pathway